36948-76-2
Chemical Structure
Oroxylin A-7-O-glucuronide
Synonym(s): Oroxyloside; Oroxylin A-7-O-β-D-glucuronide
- CAS. Nr.: 36948-76-2
- Formula:C22H20O11
- Molecular Weight:460.39
IUPAC Name: (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-((5-hydroxy-6-methoxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
InChIKey: QXIPXNZUEQYPLZ-QSUZLTIMSA-N
SMILES: OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)=C1OC
Biological Activity: Oroxylin A-7-O-glucuronide (oroxyloside) is an orally active flavonoid glucuronide and metabolite of Oroxylin A (HY-N0560). Oroxylin A-7-O-glucuronide can be extracted from the dried root of Scutellaria baicalensis. Oroxylin A-7-O-glucuronide exhibits prolyl oligopeptidase inhibitory activity. Oroxylin A-7-O-glucuronide inhibits the JNK pathway, upregulates PPARγ, and inhibits NF-κB p65 nuclear translocation. Oroxylin A-7-O-glucuronide reduces cytokine (IL-1β, IL-6) production. Oroxylin A-7-O-glucuronide exhibits anti-angiogenic, anti-tumor (glioma, liver cancer), anti-inflammatory, and hepatoprotective activities[1][2][3][4][5][6].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oroxylin A-7-O-glucuronide | 99.83% | Oroxylin A-7-O-glucuronide (oroxyloside) is an orally active flavonoid glucuronide and metabolite of Oroxylin A (HY-N0560). Oroxylin A-7-O-glucuronide can be extracted from the dried root of Scutellaria baicalensis. Oroxylin A-7-O-glucuronide exhibits prolyl oligopeptidase inhibitory activity. Oroxylin A-7-O-glucuronide inhibits the JNK pathway, upregulates PPARγ, and inhibits NF-κB p65 nuclear translocation. Oroxylin A-7-O-glucuronide reduces cytokine (IL-1β, IL-6) production. Oroxylin A-7-O-glucuronide exhibits anti-angiogenic, anti-tumor (glioma, liver cancer), anti-inflammatory, and hepatoprotective activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oroxylin A-7-O-glucuronide (Standard) | ≥98% | Oroxylin A-7-O-glucuronide (Standard) is the analytical standard of Oroxylin A-7-O-glucuronide (HY-N2481). This product is intended for research and analytical applications. Oroxylin A-7-O-glucuronide (oroxyloside) is an orally active flavonoid glucuronide and metabolite of Oroxylin A (HY-N0560). Oroxylin A-7-O-glucuronide can be extracted from the dried root of Scutellaria baicalensis. Oroxylin A-7-O-glucuronide exhibits prolyl oligopeptidase inhibitory activity. Oroxylin A-7-O-glucuronide inhibits the JNK pathway, upregulates PPARγ, and inhibits NF-κB p65 nuclear translocation. Oroxylin A-7-O-glucuronide reduces cytokine (IL-1β, IL-6) production. Oroxylin A-7-O-glucuronide exhibits anti-angiogenic, anti-tumor (glioma, liver cancer), anti-inflammatory, and hepatoprotective activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhao K, et al. Oroxyloside inhibits angiogenesis through suppressing internalization of VEGFR2/Flk-1 in endothelial cells. J Cell Physiol. 2018 Apr;233(4):3454-3464. [Content Brief]
- [2]. Xu ZF, et al. Oroxyloside inhibits human glioma progression by suppressing proliferation, metastasis and inducing apoptosis related pathways. Biomed Pharmacother. 2018 Jan;97:1564-1574. [Content Brief]
- [3]. Liao Y, et al. Oroxyloside ameliorates acetaminophen-induced hepatotoxicity by inhibiting JNK related apoptosis and necroptosis. J Ethnopharmacol. 2020 Aug 10;258:112917. [Content Brief]
- [4]. Wang X, et al. Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB pathway through PPARγ activation. Biochem Pharmacol. 2016 Apr 15;106:70-81. [Content Brief]
- [5]. Liu Y, et al. Oroxyloside inhibits liver fibrosis and hepatocarcinogenesis dependent on hepatocyte-specific knockout of Atg5. Phytomedicine. 2025 Sep;145:157053. [Content Brief]
- [6]. Marques MR, et al. Flavonoids with prolyl oligopeptidase inhibitory activity isolated from Scutellaria racemosa Pers. Fitoterapia. 2010 Sep;81(6):552-6. [Content Brief]
